Table 2.
Association between tumor characteristics and non-detection
| Variables | Non-detection (n = 114) |
Detected (n = 74) |
P value | |
|---|---|---|---|---|
| Recurrence site | Ipsilateral | 85 (61%) | 55 (39%) | 1.000 |
| Contralateral | 27 (60%) | 18 (40%) | ||
| Both | 2 (67%) | 1 (33%) | ||
| Pathologic stage | Stage 0 | 26 (67%) | 13 (33%) | 0.357 |
| Stage 1 | 53 (63%) | 31 (37%) | ||
| Stage 2 | 35 (54%) | 30 (46%) | ||
| Histologic grade | Grade 1 | 13 (81%) | 3 (19%) | 0.249 |
| Grade 2 | 60 (62%) | 37 (38%) | ||
| Grade 3 | 37 (55%) | 30 (45%) | ||
| Unknown | 4 (50%) | 4 (50%) | ||
| LN positivity | Yes | 14 (50%) | 14 (50%) | 0.212 |
| Lymphovascular invasion | Yes | 18 (62%) | 11 (38%) | 0.864 |
| ER | Positive | 61 (64%) | 35 (36%) | 0.405 |
| PR | Positive | 61 (65%) | 33 (35%) | 0.232 |
| HER2 | Negative | 74 (57%) | 55 (43%) | 0.161 |
| Positive | 36 (65%) | 19 (35%) | ||
| Equivocal | 4 (100%) | 0 (0%) | ||
| Molecular subtype | Luminal A | 51 (61%) | 32 (39%) | 0.211 |
| Luminal B | 17 (71%) | 7 (29%) | ||
| HER2 | 19 (61%) | 12 (39%) | ||
| TN* | 23 (50%) | 23 (50%) | ||
| Unknown | 4 (100%) | 0 (0%) | ||
Note—The numbers in parentheses are percentages
*TN triple negative